Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 Study

Highlight

– Ivosidenib (IVO), an oral inhibitor targeting mutant IDH1, was studied as monotherapy in patients with IDH1 mutated myelodysplastic neoplasm/syndrome (MDS).